Argenx股价因第三季度业绩参差不齐及Vyvgart意外测试计划而下跌
· investors.com
尽管Argenx的销售业绩超出预期，但因药物Vyvgart遭遇意外测试要求，其股价在周四早盘下跌。
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
10/08/2026 Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjog...